Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
Vera Therapeutics (NASDAQ: VERA) has appointed Jason S. Carter as Chief Legal Officer, effective immediately. Carter brings over 20 years of legal experience, most recently serving as Global Head of Legal for Kite Pharma. The appointment comes as Vera prepares for its pivotal ORIGIN 3 trial of atacicept in IgAN, with topline results expected in Q2 2025 and planned BLA submission to FDA later that year. Carter's experience includes overseeing legal activities in global product launches, R&D, manufacturing, IP litigation, and M&A transactions at companies including Daiichi Sankyo, Novartis, and Baxter.
Vera Therapeutics (NASDAQ: VERA) ha nominato Jason S. Carter come Chief Legal Officer, con effetto immediato. Carter porta con sé oltre 20 anni di esperienza legale, avendo recentemente ricoperto il ruolo di Global Head of Legal per Kite Pharma. Questa nomina avviene mentre Vera si prepara per il suo fondamentale trial ORIGIN 3 di atacicept in IgAN, con risultati preliminari attesi nel secondo trimestre del 2025 e una pianificata presentazione della BLA all'FDA entro la fine di quell'anno. L'esperienza di Carter comprende la supervisione delle attività legali per il lancio di prodotti globali, R&S, produzione, contenzioso IP e transazioni M&A in aziende come Daiichi Sankyo, Novartis e Baxter.
Vera Therapeutics (NASDAQ: VERA) ha nombrado a Jason S. Carter como Chief Legal Officer, con efecto inmediato. Carter aporta más de 20 años de experiencia legal, habiendo sido más recientemente el Jefe Global de Legal en Kite Pharma. Este nombramiento llega mientras Vera se prepara para su crucial prueba ORIGIN 3 de atacicept en IgAN, con resultados preliminares esperados para el segundo trimestre de 2025 y una presentación de BLA planificada a la FDA para finales de ese año. La experiencia de Carter incluye la supervisión de actividades legales en lanzamientos de productos globales, I+D, fabricación, litigios de propiedad intelectual y transacciones de fusiones y adquisiciones en empresas como Daiichi Sankyo, Novartis y Baxter.
Vera Therapeutics (NASDAQ: VERA)는 Jason S. Carter를 Chief Legal Officer로 즉시 임명했습니다. Carter는 20년 이상의 법률 경험을 보유하고 있으며, 최근에는 Kite Pharma의 글로벌 법무 책임자로 재직했습니다. 이번 임명은 Vera가 IgAN에서 atacicept의 중요한 ORIGIN 3 시험을 준비하는 가운데 이루어졌으며, 2025년 2분기에 주요 결과가 예상되고, 같은 해 FDA에 BLA 제출이 계획되어 있습니다. Carter의 경험에는 Daiichi Sankyo, Novartis 및 Baxter와 같은 회사에서 글로벌 제품 출시, 연구 개발, 제조, 지적 재산권 소송 및 M&A 거래의 법적 활동을 감독하는 것이 포함됩니다.
Vera Therapeutics (NASDAQ: VERA) a nommé Jason S. Carter au poste de Chief Legal Officer, avec effet immédiat. Carter possède plus de 20 ans d'expérience juridique, ayant récemment occupé le poste de responsable juridique mondial chez Kite Pharma. Cette nomination intervient alors que Vera se prépare pour son essai déterminant ORIGIN 3 sur l'atacicept dans l'IgAN, avec des résultats préliminaires attendus au deuxième trimestre 2025 et une soumission de BLA prévue à la FDA plus tard cette année. L'expérience de Carter comprend la supervision des activités juridiques lors de lancements de produits mondiaux, de recherche et développement, de fabrication, de contentieux en propriété intellectuelle et de transactions de fusions et acquisitions au sein d'entreprises telles que Daiichi Sankyo, Novartis et Baxter.
Vera Therapeutics (NASDAQ: VERA) hat Jason S. Carter zum Chief Legal Officer ernannt, mit sofortiger Wirkung. Carter bringt über 20 Jahre juristische Erfahrung mit, zuletzt als Global Head of Legal bei Kite Pharma tätig. Die Ernennung erfolgt, während Vera sich auf die entscheidende ORIGIN 3-Studie zu Atacicept bei IgAN vorbereitet, deren vorläufige Ergebnisse für das zweite Quartal 2025 erwartet werden und die geplante Einreichung eines BLA beim FDA noch in diesem Jahr erfolgen soll. Carters Erfahrung umfasst die Überwachung rechtlicher Aktivitäten bei globalen Produkteinführungen, Forschung und Entwicklung, Produktion, IP-Rechtsstreitigkeiten und M&A-Transaktionen in Unternehmen wie Daiichi Sankyo, Novartis und Baxter.
- Company is on track for ORIGIN 3 trial topline results in Q2 2025
- Planned BLA submission to FDA in 2025
- Strengthened leadership team with experienced legal executive
- None.
BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jason S. Carter as Chief Legal Officer, effective immediately.
“We are excited to have Jason join our growing team. With our pivotal ORIGIN 3 trial of atacicept in IgAN on track to announce topline results in the second quarter of 2025 and planned BLA submission to the FDA anticipated later in the year, pending data, we are actively building out our team with experienced professionals who will help us successfully enter our next phase as a company,” said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. “Jason brings a wealth of practical and strategic experience in supporting companies through regulatory approvals, commercialization, and intellectual property management.”
“It is a privilege to join the Vera team and be part of the Company’s mission to bring safe and effective therapies to patients with high unmet needs,” commented Mr. Carter. “I look forward to supporting the advancement of Vera’s lead asset, atacicept, as a potential best-in-class disease-modifying treatment option for patients with IgAN, as well as a potential therapy for multiple other autoimmune kidney diseases.”
Mr. Carter brings over 20 years of experience as an attorney providing counsel to public and private companies across a wide spectrum of life sciences, biotechnology, and large pharmaceutical companies. Mr. Carter has recently served as Global Head of Legal for Kite Pharma, Inc., where he oversaw legal and compliance activities supporting global product launches, R&D activities, manufacturing innovation and expansion, high-impact IP litigation, and M&A transactions. Prior to Kite, Mr. Carter served in a variety of senior legal roles, including at Daiichi Sankyo, Novartis, and Baxter. Earlier in his career, Mr. Carter practiced as an M&A and corporate securities attorney with Jenner & Block, and Vorys, Sater, Seymour & Pease. Mr. Carter serves on the board of advisors for Family Reach/More Moments More Memories, a leading patient centered non-profit. Mr. Carter holds a J.D. from University of Wisconsin-Madison Law School and a bachelor’s degree in political science from Temple University.
About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com
About Atacicept
Atacicept is an investigational recombinant fusion protein that contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) receptor that binds to the cytokines B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL). These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases, including IgAN and lupus nephritis.
The Phase 2b ORIGIN clinical trial of atacicept in IgAN met its primary and key secondary endpoints, with statistically significant and clinically meaningful proteinuria reductions and stabilization of eGFR versus placebo through 36 weeks. The safety profile during the randomized period was comparable between atacicept and placebo. Through 96 weeks, atacicept demonstrated further reductions in Gd-IgA1, hematuria, and proteinuria, as well as stabilization of eGFR reflecting a profile consistent with that of the general population without IgAN.
Atacicept has received FDA Breakthrough Therapy Designation for the treatment of IgAN, which reflects the FDA’s determination that, based on an assessment of data from the Phase 2b ORIGIN clinical trial, atacicept may demonstrate substantial improvement on a clinically significant endpoint over available therapies for patients with IgAN. Vera believes atacicept is positioned for best-in-class potential, targeting B cells to reduce autoantibodies and having been administered to more than 1,500 patients in clinical studies across different indications.
Forward-looking Statements
Statements contained in this press release regarding matters, events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, atacicept’s potential to be a disease-modifying treatment option for patients with IgAN, as well as a potential therapy for multiple other autoimmune kidney diseases and Vera’s expectations regarding timing of data presentations and regulatory submissions. Because such statements are subject to risk and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “will,” “may”, “plan,” “on track,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Vera’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks related to the regulatory approval process, results of earlier clinical trials may not be obtained in later clinical trials, preliminary results may not be predictive of topline results, risks and uncertainties associated with Vera’s business in general, the impact of macroeconomic and geopolitical events, and the other risks described in Vera’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Vera undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Madelin Hawtin
LifeSci Communications
MHawtin@lifescicomms.com
FAQ
When will Vera Therapeutics (VERA) announce ORIGIN 3 trial results?
Who is the new Chief Legal Officer at Vera Therapeutics (VERA)?
When does Vera Therapeutics (VERA) plan to submit BLA to FDA for atacicept?
